Latifa Zekri

2.1k total citations
30 papers, 840 citations indexed

About

Latifa Zekri is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Latifa Zekri has authored 30 papers receiving a total of 840 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 14 papers in Immunology and 10 papers in Molecular Biology. Recurrent topics in Latifa Zekri's work include CAR-T cell therapy research (16 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Immune Cell Function and Interaction (6 papers). Latifa Zekri is often cited by papers focused on CAR-T cell therapy research (16 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Immune Cell Function and Interaction (6 papers). Latifa Zekri collaborates with scholars based in Germany, France and Australia. Latifa Zekri's co-authors include Elisa Izaurralde, Eric Huntzinger, Joerg E. Braun, Jamal Tazi, Duygu Kuzuoğlu‐Öztürk, Helmut R. Salih, Gundram Jung, Karim Chébli, Tatsuji Nishihara and Jonas S. Heitmann and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and The EMBO Journal.

In The Last Decade

Latifa Zekri

26 papers receiving 840 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Latifa Zekri Germany 14 630 185 172 140 57 30 840
Erik H. Knelson United States 15 397 0.6× 109 0.6× 214 1.2× 183 1.3× 15 0.3× 22 703
Fatima Dkhissi France 13 487 0.8× 106 0.6× 174 1.0× 62 0.4× 42 0.7× 19 689
Grace Chung United States 12 490 0.8× 163 0.9× 302 1.8× 40 0.3× 76 1.3× 24 734
Daniel Domínguez United States 15 1.2k 1.9× 241 1.3× 85 0.5× 77 0.6× 15 0.3× 37 1.4k
Christine Vissinga United States 10 798 1.3× 289 1.6× 316 1.8× 216 1.5× 62 1.1× 15 1.1k
Kyong-Rim Kieffer-Kwon United States 9 617 1.0× 79 0.4× 87 0.5× 207 1.5× 25 0.4× 10 791
Chhaya Das United States 11 499 0.8× 45 0.2× 83 0.5× 156 1.1× 30 0.5× 12 649
Shengrong Lin China 9 711 1.1× 187 1.0× 56 0.3× 54 0.4× 11 0.2× 18 845
Feng‐Ting Huang Taiwan 11 383 0.6× 60 0.3× 77 0.4× 250 1.8× 52 0.9× 14 616
Liusheng He United States 11 558 0.9× 136 0.7× 111 0.6× 109 0.8× 12 0.2× 12 707

Countries citing papers authored by Latifa Zekri

Since Specialization
Citations

This map shows the geographic impact of Latifa Zekri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Latifa Zekri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Latifa Zekri more than expected).

Fields of papers citing papers by Latifa Zekri

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Latifa Zekri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Latifa Zekri. The network helps show where Latifa Zekri may publish in the future.

Co-authorship network of co-authors of Latifa Zekri

This figure shows the co-authorship network connecting the top 25 collaborators of Latifa Zekri. A scholar is included among the top collaborators of Latifa Zekri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Latifa Zekri. Latifa Zekri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Greiner, Suzanne, Martina S. Lutz, Ilona Hagelstein, et al.. (2025). T cell-engaging CD276xCD3 bispecific antibody for treatment of endometrial cancer. Journal of Translational Medicine. 23(1). 825–825.
2.
Hagelstein, Ilona, et al.. (2025). Fc-optimized CD276 antibody enhances NK cell activation against non-small cell lung cancer. Frontiers in Immunology. 16. 1624751–1624751.
3.
Jung, Jinwon, Bora Lee, Jonghwa Won, et al.. (2025). CLEC12A-directed immunocytokine with target cell–restricted IL-15 activity for treatment of acute myeloid leukemia. Frontiers in Immunology. 16. 1561823–1561823.
4.
Zekri, Latifa, Stefanie Müller, Jonas S. Heitmann, et al.. (2025). Abstract 3797: Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of CD3-bispecifics and mitigate T cell exhaustion. Cancer Research. 85(8_Supplement_1). 3797–3797.
5.
Zekri, Latifa, Ilona Hagelstein, Melanie Märklin, et al.. (2024). Immunocytokines with target cell–restricted IL-15 activity for treatment of B cell malignancies. Science Translational Medicine. 16(737). eadh1988–eadh1988. 6 indexed citations
6.
Hagelstein, Ilona, Latifa Zekri, Gundram Jung, et al.. (2024). Targeting CD276 for T cell-based immunotherapy of breast cancer. Journal of Translational Medicine. 22(1). 902–902. 5 indexed citations
7.
Hagelstein, Ilona, Martina S. Lutz, Stefanie Müller, et al.. (2024). Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody. Blood Cancer Journal. 14(1). 67–67. 7 indexed citations
8.
Zekri, Latifa, Martina S. Lutz, Stefanie Mueller, et al.. (2023). An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers. Molecular Therapy. 31(4). 1033–1045. 27 indexed citations
9.
Zekri, Latifa, Natalia Ruétalo, Mary Christie, et al.. (2023). Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro. Frontiers in Immunology. 14. 1112505–1112505. 4 indexed citations
10.
Lutz, Martina S., Latifa Zekri, Susanne Berchtold, et al.. (2023). IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer. Frontiers in Immunology. 14. 1163136–1163136. 13 indexed citations
11.
Hagelstein, Ilona, Clemens Hinterleitner, Melanie Märklin, et al.. (2022). B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma. Frontiers in Immunology. 13. 1002898–1002898. 13 indexed citations
12.
Zekri, Latifa, Martina S. Lutz, Ilona Hagelstein, et al.. (2022). Abstract 2865: CC-3, an IgG-based B7-H3xCD3 bispecific antibody for targeting of gastrointestinal cancers. Cancer Research. 82(12_Supplement). 2865–2865. 2 indexed citations
13.
Kauer, Joseph, Stefanie Müller, Melanie Märklin, et al.. (2020). Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies. Journal for ImmunoTherapy of Cancer. 8(1). e000621–e000621. 38 indexed citations
14.
Zekri, Latifa, et al.. (2019). An Fc-Optimized CD133 Antibody for Induction of Natural Killer Cell Reactivity Against Colorectal Cancer. Cancers. 11(6). 789–789. 13 indexed citations
15.
Schlegel, Patrick, Latifa Zekri, Sabine Schleicher, et al.. (2019). Abstract A131: Targeting B7-H3 (CD276) in neuroblastoma: In vitro evaluation of Fc-optimized antibodies and immunocytokines. Cancer Immunology Research. 7(2_Supplement). A131–A131. 2 indexed citations
16.
Nishihara, Tatsuji, Latifa Zekri, Joerg E. Braun, & Elisa Izaurralde. (2013). miRISC recruits decapping factors to miRNA targets to enhance their degradation. Nucleic Acids Research. 41(18). 8692–8705. 66 indexed citations
17.
Zekri, Latifa, Duygu Kuzuoğlu‐Öztürk, & Elisa Izaurralde. (2013). GW182 proteins cause PABP dissociation from silenced miRNA targets in the absence of deadenylation. The EMBO Journal. 32(7). 1052–1065. 83 indexed citations
18.
Huntzinger, Eric, et al.. (2010). Two PABPC1-binding sites in GW182 proteins promote miRNA-mediated gene silencing. The EMBO Journal. 29(24). 4146–4160. 86 indexed citations
19.
Zekri, Latifa, et al.. (2009). The Silencing Domain of GW182 Interacts with PABPC1 To Promote Translational Repression and Degradation of MicroRNA Targets and Is Required for Target Release. Molecular and Cellular Biology. 29(23). 6220–6231. 138 indexed citations
20.
Tazi, Jamal, Johann Soret, Latifa Zekri, et al.. (2004). Selective Inhibition of Topoisomerase I and Various Steps of Spliceosome Assembly by Diospyrin Derivatives. Molecular Pharmacology. 67(4). 1186–1194. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Erik H. Knelson Breakdown of academic impact, for papers by Fatima Dkhissi Breakdown of academic impact, for papers by Grace Chung Breakdown of academic impact, for papers by Daniel Domínguez Breakdown of academic impact, for papers by Christine Vissinga Breakdown of academic impact, for papers by Kyong-Rim Kieffer-Kwon Breakdown of academic impact, for papers by Chhaya Das Breakdown of academic impact, for papers by Shengrong Lin Breakdown of academic impact, for papers by Feng‐Ting Huang Breakdown of academic impact, for papers by Liusheng He
Rankless by CCL
2026